PMID- 20202485
OWN - NLM
STAT- MEDLINE
DCOM- 20100908
LR  - 20100413
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 10
IP  - 5
DP  - 2010 May
TI  - Administered CpG oligodeoxynucleotide induces mRNA expression of CXC and CC 
      chemokines at the intestinal mucosa and PBMCs in piglets.
PG  - 611-8
LID - 10.1016/j.intimp.2010.02.013 [doi]
AB  - Oligonucleotides containing CpG motifs (CpG ODN) are known to be potent 
      stimulators of the innate immune system in vitro and in vivo. We therefore 
      investigated if intranasal (IN)-mucosal or intramuscular (IM)-systemic 
      administration of CpG ODN could enhance innate immunity in the intestinal mucosa 
      and peripheral blood mononuclear cells (PBMCs) in piglets. Repeated IN or IM 
      administration of CpG ODN significantly increased local/systemic mRNA expression 
      of the CC chemokines macrophage inflammatory protein 1beta (MIP-1beta) and 
      monocyte chemoattractant protein-1 (MCP-1) and CXC chemokine gamma 
      interferon-inducible protein 10 (IP-10) and percentages of macrophages and cDCs 
      in the intestine (jejunum, caecum and colon) and PBMCs by different kinetics. IN 
      delivery of CpG ODN induced much stronger chemokine responses than IM delivery at 
      intestinal mucosas, whereas IN delivery of CpG ODN induced some weaker chemokine 
      responses than IM delivery in PBMCs. These findings suggest that IN 
      administration of 100mug/kg-CpG ODN without antigen codelivery may represent a 
      valuable strategy for induction of innate immunity against infection.
CI  - Copyright 2010 Elsevier B.V. All rights reserved.
FAU - Cheng, Qing
AU  - Cheng Q
AD  - College of Life Sciences, South China Agricultural University, Guangzhou 510642, 
      China.
FAU - Xu, Chenchao
AU  - Xu C
FAU - Zhang, Linghua
AU  - Zhang L
FAU - Li, Jiaoqing
AU  - Li J
FAU - Cao, Ting
AU  - Cao T
FAU - Zhang, Meirong
AU  - Zhang M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100302
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Pyrimidinones)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thiazoles)
RN  - 89367-92-0 
      (5(4'-hydroxybenzylidenoimino)-3-methylisothiazolo(5,4-d)pyrimidine-(7H)-4,6-dione)
SB  - IM
MH  - Administration, Intranasal
MH  - Animals
MH  - Cell Count
MH  - Cell Movement/drug effects
MH  - Chemokine CCL2/*biosynthesis/genetics
MH  - Chemokine CCL4/*biosynthesis/genetics
MH  - CpG Islands/genetics
MH  - Dendritic Cells/pathology
MH  - Immunity, Innate
MH  - Injections, Intramuscular
MH  - Intestinal Mucosa/*drug effects/immunology/metabolism/pathology
MH  - Leukocytes, Mononuclear/drug effects/immunology/metabolism/pathology
MH  - Macrophages/pathology
MH  - Oligodeoxyribonucleotides/*administration & dosage/genetics
MH  - Pyrimidinones/metabolism
MH  - RNA, Messenger/*analysis
MH  - Swine
MH  - Thiazoles/metabolism
MH  - Vaccination
EDAT- 2010/03/06 06:00
MHDA- 2010/09/09 06:00
CRDT- 2010/03/06 06:00
PHST- 2009/09/16 00:00 [received]
PHST- 2010/01/09 00:00 [revised]
PHST- 2010/02/22 00:00 [accepted]
PHST- 2010/03/06 06:00 [entrez]
PHST- 2010/03/06 06:00 [pubmed]
PHST- 2010/09/09 06:00 [medline]
AID - S1567-5769(10)00072-X [pii]
AID - 10.1016/j.intimp.2010.02.013 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2010 May;10(5):611-8. doi: 10.1016/j.intimp.2010.02.013. 
      Epub 2010 Mar 2.